Davita (NYSE:DVA) was upgraded by analysts at TheStreet from a “c” rating to a “b-” rating in a note issued to investors on Thursday.
A number of other research firms have also recently weighed in on DVA. JPMorgan Chase & Co. lifted their target price on shares of Davita from $4.90 to $84.00 and gave the company a “strong-buy” rating in a research note on Thursday, December 7th. Robert W. Baird restated a “hold” rating and set a $63.00 target price on shares of Davita in a research note on Friday, November 10th. Citigroup upgraded shares of Davita from a “neutral” rating to a “buy” rating and lifted their target price for the company from $67.71 to $82.00 in a research note on Monday, December 11th. SunTrust Banks set a $70.00 target price on shares of Davita and gave the company a “hold” rating in a research note on Thursday, December 7th. Finally, Zacks Investment Research cut shares of Davita from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, four have given a buy rating and two have assigned a strong buy rating to the company’s stock. Davita currently has a consensus rating of “Hold” and a consensus target price of $76.00.
Davita (DVA) opened at $75.53 on Thursday. The company has a debt-to-equity ratio of 1.79, a quick ratio of 1.35 and a current ratio of 1.40. Davita has a one year low of $52.51 and a one year high of $75.60. The firm has a market cap of $13,840.00, a price-to-earnings ratio of 28.94, a P/E/G ratio of 14.93 and a beta of 0.96.
Davita announced that its Board of Directors has approved a stock repurchase program on Tuesday, October 10th that authorizes the company to repurchase $1.50 billion in outstanding shares. This repurchase authorization authorizes the company to reacquire shares of its stock through open market purchases. Stock repurchase programs are often an indication that the company’s leadership believes its shares are undervalued.
In other Davita news, insider Charles Berg sold 7,048 shares of the business’s stock in a transaction on Monday, December 11th. The shares were sold at an average price of $69.24, for a total value of $488,003.52. Following the sale, the insider now owns 5,359 shares in the company, valued at approximately $371,057.16. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Javier Rodriguez sold 22,532 shares of the business’s stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $67.48, for a total transaction of $1,520,459.36. Following the completion of the sale, the chief executive officer now owns 210,317 shares in the company, valued at approximately $14,192,191.16. The disclosure for this sale can be found here. In the last quarter, insiders sold 117,937 shares of company stock worth $8,028,379. Corporate insiders own 2.10% of the company’s stock.
Several institutional investors have recently bought and sold shares of DVA. Schroder Investment Management Group increased its holdings in shares of Davita by 769.0% in the 3rd quarter. Schroder Investment Management Group now owns 434,191 shares of the company’s stock worth $25,387,000 after buying an additional 384,224 shares during the last quarter. Canada Pension Plan Investment Board increased its holdings in shares of Davita by 14.7% in the 3rd quarter. Canada Pension Plan Investment Board now owns 444,358 shares of the company’s stock worth $26,390,000 after buying an additional 56,988 shares during the last quarter. Speece Thorson Capital Group Inc. increased its holdings in shares of Davita by 14.5% in the 3rd quarter. Speece Thorson Capital Group Inc. now owns 321,182 shares of the company’s stock worth $19,075,000 after buying an additional 40,667 shares during the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH increased its holdings in shares of Davita by 1,987.3% in the 3rd quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH now owns 41,746 shares of the company’s stock worth $2,448,000 after buying an additional 39,746 shares during the last quarter. Finally, Oak Associates Ltd. OH increased its holdings in shares of Davita by 21.1% in the 2nd quarter. Oak Associates Ltd. OH now owns 185,195 shares of the company’s stock worth $11,993,000 after buying an additional 32,285 shares during the last quarter. Hedge funds and other institutional investors own 87.94% of the company’s stock.
WARNING: “Davita (DVA) Stock Rating Upgraded by TheStreet” was originally reported by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this news story can be viewed at https://www.com-unik.info/2018/01/06/davita-dva-stock-rating-upgraded-by-thestreet.html.
DaVita Inc, formerly DaVita HealthCare Partners Inc, operates two divisions: DaVita Kidney Care (Kidney Care) and DaVita Medical Group (DMG). The Kidney Care division consists of its the United States dialysis and related lab services, its ancillary services and strategic initiatives, including its international operations, and its corporate administrative support.
What are top analysts saying about Davita? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Davita and related companies.